Baader Bank Aktiengesellschaft Sells 729 Shares of Qiagen (NYSE:QGEN)

Baader Bank Aktiengesellschaft reduced its stake in Qiagen (NYSE:QGEN) by 1.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 49,214 shares of the company’s stock after selling 729 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Qiagen were worth $2,194,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Prentiss Smith & Co. Inc. grew its stake in shares of Qiagen by 1.9% in the fourth quarter. Prentiss Smith & Co. Inc. now owns 87,583 shares of the company’s stock valued at $3,900,000 after acquiring an additional 1,597 shares in the last quarter. Blue Trust Inc. raised its position in shares of Qiagen by 7.0% in the fourth quarter. Blue Trust Inc. now owns 8,990 shares of the company’s stock valued at $410,000 after buying an additional 585 shares in the last quarter. Geneos Wealth Management Inc. raised its position in shares of Qiagen by 41.5% in the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company’s stock valued at $38,000 after buying an additional 251 shares in the last quarter. RFG Advisory LLC bought a new stake in shares of Qiagen in the fourth quarter valued at approximately $234,000. Finally, Ballentine Partners LLC acquired a new stake in Qiagen during the fourth quarter worth approximately $241,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Trading Down 5.7 %

Shares of Qiagen stock opened at $43.81 on Thursday. The firm has a market capitalization of $10.00 billion, a PE ratio of 112.32, a price-to-earnings-growth ratio of 3.49 and a beta of 0.37. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. The firm’s 50 day moving average is $44.81 and its 200 day moving average is $44.37. Qiagen has a 1 year low of $40.15 and a 1 year high of $49.30.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Morgan Stanley reiterated an “equal weight” rating and set a $48.00 target price (down from $50.00) on shares of Qiagen in a research report on Monday, January 6th. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a report on Thursday, October 17th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $54.00 price target (up previously from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Qiagen has a consensus rating of “Moderate Buy” and an average price target of $51.50.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.